Eli Lilly and Company (NYSE:LLY), a US-based pharmaceutical company, announced on Friday that it has named Mary Lynne Hedley, PhD as its new director effective 15 May 2022.
Dr Hedley is to serve both the Science & Technology Committee and the Ethics and Compliance Committee.
Dr Hedley is an immunologist and cancer cell biologist and has served as a senior scientific fellow at the Broad Institute of MIT and Harvard. She has also worked as director, president, and chief operating officer at TESARO, Inc, and has served as executive vice president and chief science officer of Abraxis Bioscience, Inc.
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Flamingo Therapeutics names new director
Merck reports lung cancer trial failed to meet endpoints
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886
University of Saskatchewan Partners with SOPHiA GENETICS in landmark ovarian cancer trial